Bristol-Myers Squibb Videx
Supplemental NDA for once-daily dosing does not include an enteric-coated version (1"The Pink Sheet," Sept. 13, p. 19). Bristol is developing a version of the drug that should eliminate the need for buffers and antacids, the company said
You may also be interested in...
Bristol Myers Squibb has submitted a supplemental NDA for the antiretroviral drug Videx with once-daily dosing. Filed April 30, the application was granted a six-month priority review ending October 30, the company recently announced.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials